Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | UBE2M | P61081 | 4/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568471 | 1.00 | MAPT (0.37) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL29851886 | 1.00 | MAPT (0.37) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL25726420 | 0.91 | MAPT (0.39) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL25732384 | 0.88 | UBE2M (0.39) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL29851908 | 0.88 | UBE2M (0.41) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL23539459 | 0.88 | UBE2M (0.41) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL23536409 | 0.87 | KDM4E (0.38) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL23568987 | 0.87 | KDM4E (0.38) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL25732778 | 0.86 | NPC1 (0.42) | MAPTUBE2MDCUN1D1LMNAPOLB | |
| SCHEMBL25726365 | 0.85 | MAPT (0.36) | MAPTUBE2MDCUN1D1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4620470-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615455-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250059164-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024264017-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4076520-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076524-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115052627-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2022027058-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885UBE2M 180/4885DCUN1D1 1560/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | MAPT 3520/4885UBE2M 1386/4885DCUN1D1 3285/4885 |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | MAPT 3759/4885UBE2M 464/4885DCUN1D1 1033/4885 |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | MAPT 2575/4885UBE2M 37/4885DCUN1D1 650/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885UBE2M 180/4885DCUN1D1 1560/4885 |
| US-20250059164-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885UBE2M 180/4885DCUN1D1 1560/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885UBE2M 180/4885DCUN1D1 1560/4885 |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | MAPT 3759/4885UBE2M 464/4885DCUN1D1 1033/4885 |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885UBE2M 180/4885DCUN1D1 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.